Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Potyó

P2.01-95 Assesment the Fitness for Chemotherapy of NSCLC Patients Using 6MWT

Journal of Thoracic Oncology

English

Related publications

P2.01-60 Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients

Journal of Thoracic Oncology

English

P2.01-050 Predicting Risk of Hospitalization in Patients With NSCLC Receiving Chemotherapy Using the LCSS 3-Item Global Index (3-Igi)

Journal of Thoracic Oncology

English

P2.01-87 Profiling the Symptom Burden of Patients With Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data

Journal of Thoracic Oncology

English

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

Journal of Thoracic Oncology

English

P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients With Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

The Effect of Consolidation Chemotherapy for LA-NSCLC Patients Receiving Concurrent Chemoradiotherapy

Journal of Clinical and Analytical Medicine

Medicine

2017

English

P2.01-074 Wait and See: A Favorable Alternative for R-M1a and S-M1a NSCLC Patients

Journal of Thoracic Oncology

English

P2.01-52 Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients

Journal of Thoracic Oncology

English

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Potyó

P2.01-95 Assesment the Fitness for Chemotherapy of NSCLC Patients Using 6MWT

Related publications

P2.01-60 Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients

P2.01-050 Predicting Risk of Hospitalization in Patients With NSCLC Receiving Chemotherapy Using the LCSS 3-Item Global Index (3-Igi)

P2.01-87 Profiling the Symptom Burden of Patients With Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data

P2.01-48 Predictive Factors in NSCLC Patients With Stage IIIB/IV Treated With First Line Platinum-Doublet Chemotherapy

P2.01-113 Prognostic Roles of Neoadjuvant and Adjuvant Chemotherapy for Treating Patients With Operable Stage III-N2 Non-Small Cell Lung Cancer (NSCLC)

The Effect of Consolidation Chemotherapy for LA-NSCLC Patients Receiving Concurrent Chemoradiotherapy

P2.01-074 Wait and See: A Favorable Alternative for R-M1a and S-M1a NSCLC Patients

P2.01-52 Identification of Leptomeningeal Metastasis-Specific Exosomal miRNA Signatures in Cerebrospinal Fluids of NSCLC Patients

P2.01-127 Efficacy of Endostar Combined With Whole Brain Radiotherapy in Patients With NSCLC Brain Metastases